Drug Trial Radar · NCT05733598
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Last checked: Nov 19, 2026Latest source record: Apr 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Aug 1, 2024
Primary completion
Dec 1, 2027
Study completion Jul 1, 2028
Sponsor
- Lead sponsor
- Replimune, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab (Cohorts 1a and 1b) and RP2 monotherapy (Cohort 2) in the as second line treatment in patients with locally advanced unresectable, recurrent, and/or metastatic HCC and in combination with durvalumab as treatment in patients with unresectable locally advanced or metastatic BTC.
Conditions
- Hepatocellular Carcinoma
- Biliary Tract Cancer
Interventions
RP2Biological
Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation.
BevacizumabBiological
Anti-VEGF therapy.
AtezolizumabBiological
Anti-PD-L1 monoclonal antibody.
DurvalumabBiological
Anti-PD-L1 monoclonal antibody
RP2 MonotherapyBiological
Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate per modified RECIST 1.1Time frame: From Day 1 up to 3 years after first RP2 dose of last patient.
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Beverly Hills Cancer Center
Beverly Hills, California · Recruiting
UC San Diego Moores Cancer Center
La Jolla, California · Recruiting
Sylvester Comprehensive Cancer Center (University of Miami Hospital and Clinics)
Miami, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
University of Maryland Medical Center
Baltimore, Maryland · Recruiting
Roswell Park Comprehensive Cancer Center
Buffalo, New York · Recruiting
Montefiore Medical CenterMontefiore Medical Park
The Bronx, New York · Recruiting
University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania · Recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
The West Clinic
Germantown, Tennessee · Recruiting
University of Tennessee Medical Center
Knoxville, Tennessee · Recruiting
Houston Methodist Hospital Cancer Center
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.